4,545 Shares of Danaher Corporation $DHR Acquired by Seelaus Asset Management LLC

Seelaus Asset Management LLC acquired a new position in shares of Danaher Corporation (NYSE:DHR) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,545 shares of the conglomerate’s stock, valued at approximately $1,007,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Veery Capital LLC grew its stake in shares of Danaher by 3.1% in the third quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after buying an additional 48 shares in the last quarter. Studio Investment Management LLC raised its holdings in shares of Danaher by 3.3% during the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after buying an additional 51 shares during the period. JDH Wealth Management LLC lifted its position in Danaher by 4.5% during the 1st quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after acquiring an additional 55 shares in the last quarter. OLD Second National Bank of Aurora lifted its position in Danaher by 0.5% during the 1st quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock worth $2,297,000 after acquiring an additional 57 shares in the last quarter. Finally, Adelphi Trust Co boosted its holdings in Danaher by 2.5% in the 3rd quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock worth $524,000 after acquiring an additional 57 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.7%

DHR traded up $1.63 on Wednesday, reaching $224.47. The company’s stock had a trading volume of 1,984,723 shares, compared to its average volume of 4,449,140. The stock has a market cap of $157.80 billion, a price-to-earnings ratio of 39.83, a price-to-earnings-growth ratio of 2.78 and a beta of 0.76. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The business’s 50 day moving average is $212.41 and its 200 day moving average is $195.13.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the previous year, the business earned $0.77 EPS. Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, research analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

Analyst Ratings Changes

Several brokerages have issued reports on DHR. The Goldman Sachs Group increased their price objective on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Wells Fargo & Company reduced their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. Evercore restated an “outperform” rating and issued a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. Finally, Barclays raised their price target on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $235.41.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.